Related by context. All words. (Click for frequent words.) 73 tipranavir r 71 HBeAg seroconversion 70 lopinavir r arm 70 achieved ACR# 70 Viread Emtriva Sustiva 70 sustained virological response 69 fosamprenavir 69 BARACLUDE ® 69 undetectable viral 68 HBeAg negative patients 68 oxycodone CR 68 LEXIVA r 68 clodronate 68 virologically 68 log# reduction 67 placebo dexamethasone 67 piperacillin tazobactam 67 ritonavir boosted 67 LPV r 67 undetectable HBV DNA 67 indinavir 67 complete cytogenetic response 67 PASI scores 67 mg ustekinumab 67 mcg QD 67 HbA 1c levels 67 TMC# r 67 virologic failure 67 virologic 67 virological suppression 66 nevirapine Viramune 66 APTIVUS r 66 protease inhibitor PI 66 -#.# log# 66 TPV r 66 PSA nadir 66 nadroparin 66 p = NS 66 lamivudine monotherapy 66 baseline HbA1c 66 genotype 1b 65 % CI #.#-#.# [003] 65 HIV RNA 65 caspofungin 65 comparator PI r 65 receiving ISENTRESS 65 relapsed MM 65 QTcF 65 interferon ribavirin 65 atazanavir ritonavir 65 #mg dose [002] 65 doxorubicin docetaxel 65 lumbar spine BMD 65 Flu Cy 65 TDF FTC 65 imipenem 65 REYATAZ R 65 FluCAM 65 MCyR 65 comparator arm 65 KRAS mutations occur 65 anemia hemoglobin 65 sustained virologic response 65 prednisone prednisolone 65 antiretroviral naïve 65 genotypic resistance 65 pCR 65 lopinavir r 65 receiving VICTRELIS 65 virologic response 65 Aptivus ® 65 PREZISTA ritonavir 64 unboosted 64 ritonavir Norvir 64 HBeAg 64 CR nPR 64 fluticasone salmeterol 64 salmeterol fluticasone 64 FluCAM arm 64 lopinavir 64 5-FU/LV 64 abacavir lamivudine 64 Viread Emtriva 64 ritonavir boosted lopinavir 64 pegylated interferon alpha 64 #mg/day [001] 64 REYATAZ r arm 64 APTIVUS R 64 coinfected 64 PREZISTA r 64 rimonabant #mg 64 atorvastatin #mg 64 DAS# CRP 64 darunavir 64 HBV DNA 64 #mg BID [001] 64 Engerix B 64 clinically evaluable 64 mcg albinterferon alfa 2b 64 plus methotrexate 64 cinacalcet 63 Peg IFN 63 CANCIDAS 63 mcg BID 63 efavirenz EFV 63 NNRTI resistance 63 pegylated liposomal doxorubicin 63 serum urate levels 63 CD4 + cell 63 peginterferon alfa 2b 63 mg kg dose 63 clinically evaluable patients 63 undetectable viral load 63 low dose ritonavir 63 response CCyR 63 microbiological eradication 63 protease inhibitors PIs 63 peginterferon alfa 2a 63 tipranavir 63 adefovir 63 FFNS 63 Hb A1C 63 CIMZIA TM certolizumab pegol 63 morphometric vertebral fractures 63 #mg BID [003] 63 seroconverted 63 antiretroviral naive 63 ertapenem 63 ibandronate 63 micafungin 63 CCyR 63 doxorubicin cyclophosphamide 63 amoxicillin clavulanate 63 biochemical relapse 63 pegIFN 63 biphasic insulin aspart 63 MADRS score 63 dalteparin 63 KRAS mutant tumors 63 CIN3 63 hepatitis C genotype 63 RGT arm 63 TEAEs 63 seroprotection 63 tipranavir ritonavir 63 achieving PASI 63 steroid dexamethasone 63 mitoxantrone 63 % CI #.#-#.# [007] 63 adjunctive placebo 63 tapentadol ER 63 deep venous thromboses 63 achieved CCyR 63 % Confidence Interval 63 Fludara 63 4mg/kg 63 % CI #.#-#.# [008] 63 doxazosin 63 Pred Forte 62 atazanavir Reyataz 62 endoscopic remission 62 plus dexamethasone 62 darunavir r 62 Hazard Ratio 62 boosted protease inhibitor 62 atazanavir sulfate 62 mg BID 62 tamoxifen Nolvadex ® 62 microbiologically evaluable 62 undetectable viral loads 62 hematologic toxicity 62 log# copies mL 62 ARB telmisartan 62 HIV uninfected 62 octreotide LAR 62 ug dose 62 amprenavir 62 mitoxantrone plus 62 nelfinavir 62 adenoma recurrence 62 Platelet counts 62 HbA1C 62 pT3 62 PEG Interferon alfa 62 Lantus ® 62 achieved PASI 62 EDSS scores 62 nondiabetic patients 62 hemoglobin A1c levels 62 IOP lowering 62 SCIg 62 poor metabolizers 62 HBeAg positive 62 nicardipine 62 coinfected patients 62 doripenem 62 mg/m2 dose 62 pegylated interferon alfa 2b 62 Pegasys peginterferon alfa 2a 62 Copegus ribavirin 62 glycated hemoglobin levels 62 urate lowering therapy 62 null responder 62 CI #.#-#.# [002] 62 ACR# response 62 tenofovir FTC 62 abacavir Ziagen 62 TMP SMX 62 evaluable subjects 62 HbA1C levels 62 virological failure 62 zidovudine lamivudine 62 tenofovir emtricitabine 62 SVR# 62 achieved sustained virological 62 ritonavir boosted atazanavir 62 q8h 62 β blockers 62 fluvastatin 62 peg interferon 62 baseline LDH 62 oral FTY# 62 pooled comparator 62 gm dl 62 CIMZIA TM 62 viral titers 62 adalimumab Humira 62 ribavirin therapy 62 achieved sustained virologic 62 mcg kg REBETOL 62 recurrent glioblastoma multiforme 62 median CD4 62 lamivudine refractory patients 62 mg QD 62 pyrazinamide 62 EDSS score 62 certolizumab 62 mcg dose 62 HBeAg positive patients 62 virologic response EVR 62 pegylated interferon alfa 61 virologic suppression 61 AZT zidovudine Retrovir 61 cEVR 61 alanine aminotransferase ALT 61 neutrophil counts 61 ACTEMRA TM 61 PegIFN RBV 61 mg hydrochlorothiazide 61 aldosterone antagonist 61 cisplatin vinorelbine 61 suboptimal adherence 61 #.#/#.# mmHg [001] 61 Free Survival PFS 61 postintervention 61 lispro 61 ALT elevation 61 oral allopurinol 61 low dose Iluvien 61 serum urate 61 paricalcitol 61 dose cohort 61 atazanavir 61 mmHg diastolic 61 mutated KRAS 61 antibody titer 61 CYPHER Stent 61 -#.# log# copies mL 61 dose ritonavir 61 highly emetogenic 61 acromegalic patients 61 mg Lucentis 61 enfuvirtide 61 COMBIVIR 61 advanced adenomas 61 binary restenosis 61 ribavirin RBV 61 FOLFIRI alone 61 mg TID 61 Kivexa 61 NeoRecormon 61 viral suppression 61 median survivals 61 ethambutol 61 #mmHg [001] 61 Postoperatively 61 tolterodine ER 61 evaluating tivozanib 61 REYATAZ ® 61 Celsentri Selzentry 61 oral diclofenac 61 Pegylated Interferon 61 virologic failures 61 perioperative mortality 61 undetectable hepatitis C 61 transaminase elevations 61 bezafibrate 61 FOLFOX4 61 tirofiban 61 lopinavir ritonavir Kaletra 61 adalimumab 61 Viral load 61 mIU ml 61 plus aztreonam 61 Lipitor #mg 61 efavirenz Sustiva 61 Betaferon R 61 voriconazole 61 baseline A1C 61 plasma HCV RNA 61 active comparator 61 virological response 61 serum creatinine levels 61 incontinence episodes 61 INTELENCE 61 VELCADE melphalan 61 salmeterol fluticasone propionate 61 q#h 61 HPV-#/# 61 Durezol 61 RLAI 61 PRADAXA #mg 61 corticosteroid dose 61 mmHg systolic 60 NATRECOR R 60 alanine aminotransferase 60 daily subcutaneous injections 60 platelet reactivity 60 FOLFOX6 60 Thal Dex 60 solifenacin 60 chronic HBV 60 benazepril 60 rilpivirine 60 abnormal p# biomarker 60 8mg/kg 60 preoperative chemotherapy 60 antibody titers 60 ACR# responses 60 prospectively stratified 60 lymphocyte count 60 mean baseline A1C 60 cabazitaxel 60 dapagliflozin plus 60 μg dose 60 idraparinux 60 oral Hycamtin 60 Femara letrozole 60 squamous histology 60 #mg QD [001] 60 CAELYX 60 MabThera Rituxan 60 Crohn Disease Activity 60 detectable HCV RNA 60 vicriviroc 60 interferon alfa 2a 60 severe exacerbations 60 raltegravir 60 statistically significant p = 60 venlafaxine XR 60 ABC/3TC 60 moderate renal impairment 60 CIMZIA ™ 60 recurrent venous thromboembolism 60 trimethoprim sulfamethoxazole 60 HBV DNA levels 60 XIENCE V PROMUS Stent 60 mg RDEA# 60 complete cytogenetic 60 azilsartan medoxomil 60 NRTI 60 undetectable HCV RNA 60 tenecteplase 60 daunorubicin 60 boosted atazanavir 60 recurrent VTE 60 pamidronate 60 NMIBC 60 diuretic chlorthalidone 60 d4T 60 inhaled iloprost 60 glycosylated hemoglobin levels 60 anagrelide 60 CsA 60 infusional 5-FU/LV 60 IV bisphosphonates 60 gemcitabine carboplatin 60 locoregional recurrence 60 PREZISTA rtv 60 titrated glipizide 60 #mg ATC 60 seropositivity 60 GG genotype 60 carboplatin paclitaxel 60 flutamide 60 seroconversion 60 serum potassium 60 detemir 60 K#N 60 insulin detemir 60 rosuvastatin #mg 60 postoperative chemotherapy 60 thrombocytopenic 60 dexamethasone Decadron 60 beta blocker therapy 60 Telbivudine 60 NRTI sparing 60 ddI 60 oral antidiabetic medication 60 entecavir 60 unresectable HCC 60 NRTI resistance 60 intravenous diuretics 60 ropivacaine 60 SPIRIVA ® 60 infliximab monotherapy 60 hypokalemia 60 polytherapy 60 noninferior 60 oral olanzapine 60 ALT normalization 60 REMICADE monotherapy 60 Median PFS 60 levosimendan 60 combination antiretroviral therapy 60 dexmedetomidine 60 plus OBT 60 HBeAg negative 60 APTIVUS 60 % CI #.#-#.# [006] 60 methotrexate monotherapy 60 recurrent genital herpes 60 lamivudine 60 mg simvastatin 60 antiandrogen 60 mmol l 60 #mg doses [002] 60 tenofovir DF 60 Isentress raltegravir 60 Pegasys plus Copegus 60 adriamycin 60 preintervention 60 BENICAR HCT 60 pegfilgrastim 60 chronic HCV genotype 60 3mg/kg 59 heavily pretreated 59 enalapril 59 leukopenia 59 plus gemcitabine 59 rifabutin 59 trastuzumab Herceptin ® 59 PREZISTA r arm 59 stavudine d4T 59 paclitaxel eluting stents 59 peginterferon alfa 59 partial remissions 59 azathioprine 59 fasting plasma glucose FPG 59 peginterferon alpha 2a 59 tamsulosin 59 abacavir 59 glatiramer acetate 59 patients undergoing CABG 59 BARACLUDE R 59 #.#mg/dL 59 aspirin clopidogrel 59 R entecavir 59 ritonavir boosted protease inhibitor 59 HbA1c levels 59 incidence ≥ 59 ß blockers 59 invasive ductal 59 ALVESCO 59 ARCALYST ® 59 Virologic 59 adjunctive ABILIFY 59 angiographic outcomes 59 mL/min/#.# m 2 59 HAART regimen 59 iniparib 59 mg qd 59 REYATAZ r 59 irbesartan 59 NNT = 59 resected pancreatic cancer 59 plasma uric acid 59 adefovir treated 59 mcg Albuferon 59 #OHD levels 59 confidence interval #.#-#.# 59 nadolol 59 p = .# [002] 59 highest tertile 59 -#.# mg dL [001] 59 HIV HCV coinfected 59 HCV antibody 59 thiazide diuretics 59 desvenlafaxine succinate 59 MMSE score 59 primary patency 59 HCV infected 59 β blocker 59 severe neutropenia 59 P = .# 59 lopinavir ritonavir 59 Helicobacter pylori eradication 59 nonnucleoside reverse transcriptase inhibitors 59 p = ns 59 definite stent thrombosis 59 CC genotype 59 alfa 2a 59 IFN beta 59 FTC TDF 59 genotype 1a 59 ARCOXIA 59 onset atrial fibrillation 59 ECOG PS 59 μg kg 59 FDA defined valvulopathy 59 cyclophosphamide doxorubicin vincristine 59 de novo kidney transplant 59 sUA levels 59 Fx adj 59 darunavir ritonavir 59 reinfarction 59 bisoprolol 59 S. aureus isolates 59 Ishak fibrosis score 59 annualized relapse 59 VFEND 59 ATV RTV 59 otamixaban 59 Folfox 59 divalproex sodium 59 inotropic 59 peginterferon 59 carboplatin chemotherapy 59 mycophenolate mofetil 59 ketorolac 59 locoregional disease 59 lipid lowering medications 59 stent binary restenosis 59 anthracycline taxane 59 serum PSA 59 candidemia 59 cytogenetic responses 59 #mg dose [003] 59 lipid lowering agents 59 attain statistical significance 59 NPH insulin 59 dacarbazine chemotherapy 59 leuprorelin 59 glyburide 59 urine albumin 59 BENICAR 59 overt nephropathy 59 #.#ng/ml 59 co trimoxazole 59 pT2 59 YERVOY 59 ISENTRESS 59 elevated troponin 59 intravenous bisphosphonates 59 isoproterenol 59 HER2 positive cancers 59 mg BID dose 59 microg 59 CI #.#-#.# [001] 59 ORENCIA ® 59 mitoxantrone chemotherapy 59 ezetimibe simvastatin 59 -#.# mg dL [002] 59 labetalol 59 null responder HCV 59 gemcitabine cisplatin 59 pegylated interferon alfa 2a 59 glycated hemoglobin HbA1c 59 perioperatively 59 Tumors shrank 59 seropositive patients 59 recurrent GBM 59 atheroma volume 59 IFN alfa 59 biochemical recurrence 59 ALT flares 59 inecalcitol 59 NSTE ACS 59 hepatorenal syndrome 59 achieved statistical significance 59 #mg QD [002] 59 lenalidomide Revlimid R 58 tacrolimus ointment 58 serum HBV DNA 58 estimated GFR 58 viral kinetics 58 specific antigen PSA 58 peginterferon alfa 2a #KD 58 tertile 58 RNA copies mL 58 Baseline characteristics 58 radezolid 58 elevated serum creatinine 58 colorectal adenoma 58 epoetin beta 58 BEACOPP 58 CrCl 58 3TC lamivudine Epivir 58 pentoxifylline 58 albumin excretion rate 58 monoinfected patients 58 p ≤ 58 underwent resection 58 Doxil ® 58 Alkeran 58 valacyclovir 58 Fasting plasma glucose 58 NATRECOR ® 58 molindone 58 emtricitabine tenofovir 58 receiving prophylactic anticoagulation 58 NYHA functional class 58 rFVIIa 58 VIRAMUNE 58 zoledronate 58 multivariable adjusted 58 alkylating agent 58 treatment naļve 58 cytarabine daunorubicin 58 Eloxatin R 58 del 5q MDS 58 IU mL 58 paliperidone ER 58 CIN2 + 58 FUSILEV enhances 58 CDAI score 58 mL/min/#.# m2 58 elevated ALT 58 posaconazole 58 ml kg 58 virologic responses 58 Naive Patients 58 elevated LDH 58 Pegintron 58 copies ml 58 aminotransferases 58 mcg doses 58 repigmentation 58 oral antidiabetes 58 glycosylated hemoglobin HbA1c 58 interferon alfa 2b 58 plasma renin activity 58 virologic breakthrough 58 neurodevelopmental impairment 58 tapentadol IR 58 Epivir 58 nonsignificant difference 58 neutropenic sepsis 58 receiving INTRON 58 viral loads 58 pimecrolimus cream 58 hours postdose 58 clevidipine 58 cART 58 leukocyte count 58 PegIntron 58 AmBisome 58 mg dose 58 rifapentine 58 PSADT 58 Chronic Hepatitis C 58 elevated transaminases 58 alfa 2b 58 sUA 58 glulisine 58 containing abacavir 58 intermittent dosing 58 posttreatment 58 rFSH 58 pyridostigmine 58 adefovir dipivoxil 58 CYP#D# inhibitor 58 relapsers 58 unfractionated heparin 58 hemodialysis patients 58 lenalidomide dexamethasone 58 PEG Intron 58 hip BMD 58 NNRTI resistant virus 58 peginterferon ribavirin 58 subcutaneous insulin 58 cilostazol 58 timepoint 58 TURBT 58 cells mcL 58 XIENCE V demonstrated 58 serum lipid levels 58 FOLPI 58 linezolid 58 laboratory abnormalities 58 plus MTX 58 cidofovir 58 nonmetastatic prostate cancer 58 plasma folate 58 mRCC 58 FROVA 58 canakinumab 58 unfractionated heparin UFH 58 lowest tertile 58 CDAI 58 conventional DMARDs 58 potent antiretroviral therapy 58 Tipranavir 58 hemoglobin A1c HbA1c 58 aspartate aminotransferase AST 58 STELARA ® 58 sotalol 58 hemoglobin Hb 58 concomitant medications 58 remission CR 58 intravenous vancomycin 58 nonvertebral fractures 58 trials RCTs 58 femoral neck BMD 58 aPTT 58 CHOP chemotherapy 58 efavirenz emtricitabine 58 prolactin elevation 58 HER2 expression 58 μmol L 58 Hycamtin ® 58 hypoglycemic events 58 FOLFOX4 alone 58 A1c levels 58 HCV viral 58 patients evaluable 58 Pegylated interferon 58 shorter telomere length 58 refractory AML 58 stage IIIb IV 58 KRAS wild 58 baseline Hb 58 revascularizations 58 placebo p = 58 neurologic progression 58 LV dysfunction 58 eosinophil count 58 RoACTEMRA 58 rizatriptan 58 AGILECT R 58 NIH CPSI 58 lopinavir ritonavir plus 58 segment binary restenosis 58 radiotherapy RT 58 expressors 58 teriflunomide 58 oblimersen 58 dacarbazine 58 apremilast 58 non squamous histology 58 #Gy 58 timepoints 58 docetaxel chemotherapy 58 PEG IFN 58 oxaliplatin Eloxatin 58 Gag polymorphisms 58 progression TTP 58 HCV RESPOND 2 58 #mg/m# [001] 58 intracranial hemorrhage ICH 58 seronegative 58 HCV genotype 1 58 ® lenalidomide 58 Subgroup analysis 58 LANTUS R 58 panitumumab Vectibix 58 IRLS score 58 receiving VELCADE 58 receiving antiretroviral therapy 58 advanced adenoma 58 VcMP 58 receiving highly emetogenic 57 decitabine 57 median PFS 57 metastatic CRC 57 SUVmax 57 hypophosphatemia 57 antihypertensive medications 57 mcg ml 57 Score DAS# 57 QTc prolongation 57 FOLFIRINOX 57 GnRH agonist 57 Rebetol 57 generalized edema 57 prospectively defined 57 dosing cohorts 57 prospectively enrolled 57 liver histology 57 chlorambucil 57 corifollitropin alfa 57 Dasatinib 57 log# 57 intravenous bolus injection 57 palivizumab 57 underwent CABG 57 subcutaneous enoxaparin 57 CCR5 tropic HIV 57 mg kg cohorts 57 low dose cytarabine 57 lamotrigine 57 postoperative mortality 57 plus prednisone prednisolone 57 cefuroxime 57 fasting triglyceride levels 57 biologic DMARD 57 rapid virological response 57 serum ALT 57 budesonide pMDI 57 corticosteroid therapy 57 OGTT 57 anti Xa 57 mg Proellex 57 HER2 amplification 57 log# IU mL 57 confidence interval CI 57 Kaplan Meier estimates 57 diastolic blood pressures 57 Platinol ® cisplatin 57 SGPT 57 visceral metastases 57 valsartan amlodipine 57 serum phosphorous 57 bortezomib refractory 57 peginterferon alfa 2a Pegasys 57 dose atorvastatin 57 UPDRS motor 57 HBsAg 57 IIIa inhibitors 57 trastuzumab Herceptin R 57 mg XP# 57 Cipralex ® 57 dose cytarabine 57 preoperative PSA 57 nmol liter 57 Xelox 57 complete remissions 57 clinically meaningful improvement 57 placebo fluoxetine 57 achieved mucosal healing 57 interferon beta therapy 57 Vfend 57 rituximab Rituxan 57 serum cortisol 57 Viread Emtriva SUSTIVA 57 TAXUS Stent 57 motesanib 57 virologically suppressed 57 mapatumumab 57 ACUITY trial 57 GPIIb IIIa inhibitors 57 inhospital mortality 57 Betaferon ® 57 rituximab refractory 57 PANSS scores 57 treatment naive genotype 57 gemcitabine Gemzar 57 lymphocyte counts 57 p = #.# [003] 57 mcg mL 57 mg/m2 IV 57 baseline FEV 57 simvastatin ezetimibe 57 lanthanum carbonate 57 ALT elevations 57 serum phosphate levels 57 nonvertebral fracture 57 nitazoxanide 57 estramustine 57 antiemetics 57 metoprolol tartrate 57 Scale EDSS 57 invasive carcinomas 57 Apidra ® 57 umol L 57 Crestor rosuvastatin 57 neutropenic 57 Kaplan Meier analysis 57 confidence intervals CIs 57 iPTH 57 mg eq 57 mCi m 2 57 #mg dosing 57 treat NNT 57 adjuvant tamoxifen 57 hA# 57 hemoglobin concentrations 57 aminotransferase elevations greater 57 cytogenetic response 57 severe hypoglycemic 57 alemtuzumab treated 57 prior relapsers 57 gadobutrol 57 trandolapril 57 EGFR TKI 57 ug mL 57 cyclophosphamide methotrexate 57 metastatic malignant melanoma 57 Hazard Ratio = 57 g dl 57 VTE prophylaxis 57 μg mL 57 HBeAg + 57 metastatic GIST 57 PEGINTRON TM 57 REVLIMID ® 57 nucleoside naive 57 hormone receptor negative 57 receiving PEGINTRON 57 salmeterol HFA MDI 57 proguanil 57 moderately emetogenic 57 knee extensor 57 concentration Cmax 57 pomalidomide 57 advanced neoplasia 57 adiponectin concentrations 57 COPD exacerbation 57 administered subcutaneously 57 Stent thrombosis 57 Infusion Reactions Severe 57 candesartan cilexetil 57 copies mL 57 sirolimus stent 57 iniparib BSI 57 lamivudine Epivir 57 Target Lesion Revascularization TLR 57 insulin degludec 57 timolol 57 dose cyclophosphamide 57 beta interferons 57 NNRTIs 57 antibiotic regimens 57 HCV genotype 57 oxycodone IR 57 CR CRu 57 zonisamide SR 57 neutropaenia 57 Velcade bortezomib 57 dosage regimens 57 cefepime 57 Newly Diagnosed Multiple Myeloma 57 polyp recurrence 57 COPAXONE R 57 d4T stavudine Zerit 57 microgram kg 57 null responders 57 mycophenolate mofetil MMF 57 DAPT 57 HCV RNA 57 Ramipril 57 R0 resection 57 ® emtricitabine 57 serum aminotransferase levels 57 hsCRP levels 57 HbA 1c 57 imiquimod cream 57 oral antidiabetic 57 mean baseline HbA1c 57 #ng/ml 57 rt PA 57 ZYVOX 57 docetaxel Taxotere 57 chemoradiotherapy 57 glargine 57 Index CDAI score 57 bone marrow reticulin deposition 57 Index CDAI 57 HI titers 57 DAS# [002] 57 indinavir Crixivan 57 Partial Responses 57 oral levofloxacin 57 colorectal carcinomas 57 beclomethasone dipropionate 57 CCR5 tropic 57 basal bolus regimen 57 lamivudine 3TC 57 aspartate aminotransferase 57 nonmetastatic 57 ascending dose 57 naïve HCV 57 #mg q8h 57 liver transplant recipients 57 completely resected 57 saquinavir 57 Natalizumab 57 ACR Pedi 57 EGFR mutation positive